SHINPOONG.CO

What SHINPOONG.CO does

Shinpoong Pharmaceutical (신풍제약, KRX-listed, ticker A003230) is a South Korea-based pharmaceutical company founded in 1962 and incorporated under its current form in 1986, headquartered in Gangnam, Seoul with manufacturing operations at Ansan (Banwol) and Osong, Cheongju, and approximately 770 regular employees. The company operates across three principal revenue streams: (i) a global specialty infectious-disease franchise built around Pyramax, a WHO-prequalified artemisinin-combination therapy for malaria that is registered in 22 countries and has been administered to 20M+ patients through partnerships with the Medicines for Malaria Venture (MMV) and institutional buyers such as the U.S. President's Malaria Initiative (PMI); (ii) a domestic and emerging-international branded prescription portfolio that includes Avossil/Abovir Plus (dutasteride + tadalafil fixed-dose combination, launched December 2025 — marketed as the world's first FDC for BPH), HyAlFlex (an HMDA-crosslinked hyaluronic acid viscosupplement using a proprietary cross-linking method, launched February 2026), generics, antibiotics, and the AddMiles health functional food brand; and (iii) a pipeline targeting high-value adjacencies including the SP-8203 stroke therapy in Phase 3 and a denosumab biosimilar planned for 2026.

The company makes money through a mix of channels: institutional procurement contracts for Pyramax (driven by WHO PQ, EML listing, FDA Rare Pediatric Disease Designation, and Korea CDC Malaria Treatment Guideline inclusion); domestic Korean National Health Insurance reimbursement for branded prescription products; over-the-counter sales of the AddMiles functional food brand; API synthesis and export; and royalties/licensing enabled by its expanding patent estate (e.g., 2025 Pyramax COVID-19 patents granted in the US, Europe, and Korea). Its 2025 financial profile shows revenue of 234,681M KRW (~$162M), operating profit of 14,255M KRW, and net profit of 8,389M KRW, representing a return to profitability after four loss-making years on +6.1% top-line growth, supported by a restructuring of the sales force into a hybrid direct/CSO model and a multi-year 600B+ KRW capacity investment at Osong and Ansan.

Name

SHINPOONG.CO

Legal name

신풍제약주식회사

Website

https://shinpoong.co.kr

Company type

Public

Founded year

1962

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Oral Solid Dose (OSD) Generics (HLAIABAD), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Antimalarial drugs
• Prescription pharmaceuticals
• Hyaluronic acid injections
• Health functional foods
• Active pharmaceutical ingredients

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Products: Revenue from prescription drugs (specialty pharmaceuticals, general pharmaceuticals), medical devices, and health functional foods. Main products include Pyramax (antimalarial), HyAlFlex (hyaluronic acid injection), Abovir Plus (BPH), and generic antibiotics. Health functional foods sold under AddMiles brand.
2. API (Active Pharmaceutical Ingredient) Synthesis: Manufacturing and export of active pharmaceutical ingredients for global markets. Historical strength in antibiotic API production including cefazolin, cefradine, amlodipine, atorvastatin, levofloxacin, and others. Export partnerships with African and Asian markets.
3. Technology Transfer / Licensing: Revenue from technology exports of proprietary drugs. Pyramax exported to 22+ countries. SP-8203 and HyAlFlex targeted for international technology licensing.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Shinpoong Pharmaceutical manufactures and sells specialty prescription drugs, including the WHO-prequalified antimalarial Pyramax (pyronaridine-artesunate ACT), the HMDA-crosslinked hyaluronic acid joint injection HyAlFlex for osteoarthritis, and the world's first dutasteride/tadalafil combination drug Abovir Plus for benign prostatic hyperplasia. The company also operates the AddMiles health functional food brand sold via Naver official store and open marketplaces, and manufactures APIs and finished dosage forms at its Ansan and Osong facilities.

Product overview

Shin Poong Pharmaceutical is a diversified pharmaceutical company with multiple product categories: prescription drugs (antibiotics, cardiovascular drugs, and other therapeutics), general OTC medications, medical devices, and health functional foods under the AddMiles sub-brand. Key products include Pyramax (antimalarial), Hi-Alflex Injection (hyaluronic acid joint treatment), Avossil (prostate treatment), and the AddMiles health food brand. The company also has pipeline products including SP-8203 for stroke treatment and Denosumab for osteoporosis.

Differentiator

Problem solved

Functional benefit

Brands

• 피라맥스 (Pyramax): Antimalarial drug - Pironaridine/Artesunate combination ACT treatment, WHO pre-qualified, approved in 22 countries
• 애드마일스 (AddMiles)
• 하이알플렉스주 (HyalFlex)
• 아보시알정 (Avosial)
• 메디커튼 (Medikertun)

Products and services

• Pyramax (피라맥스) Artemisinin-based combination therapy antimalarial drug (pyronaridine-artesunate), the only ACT globally approved for both P. vivax and P. falciparum malaria, used by over 20 million patients globally.
• HyAlFlex Injection (하이알플렉스주) HMDA (hexamethylenediamine) cross-linked hyaluronic acid sodium gel for intra-articular injection treating knee osteoarthritis with single-dose 5mL therapy every 6 months and improved physical stability.
• Abovir Plus / Avossil (아보시알정) World's first fixed-dose combination of dutasteride and tadalafil (0.5/5mg) for benign prostatic hyperplasia treatment, providing dual mechanism of action to reduce prostate size and improve lower urinary tract symptoms.
• AddMiles Health Functional Foods (애드마일스) Health functional food sub-brand offering milk thistle, calcium/magnesium/vitamin D, and multivitamin supplements sold via Naver official brand store and major open marketplaces.
• Multi-Vitamin ESP Formula 21 (멀티비타민 에스피 포뮬라21) Approved health functional food containing 21 multivitamins and minerals supporting energy production, immune function, antioxidant action, cell protection, and bone health.
• Medikertun (메디커튼) Anti-adhesion barrier medical product for surgical adhesion prevention.

Quantifiable outcome

• Pyramax used by over 20 million patients globally
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• Medicines for Malaria Venture (MMV)coreStrategic or Co-development Partner · 1 July 2024Long-term partnership with MMV for co-development of antimalarial drugs. MMV selected Pyramax as optimal supplier for global malaria treatment programs. MMV awarded Shin Poong the 2005 MMV Project Award for contribution to malaria R&D.
• U.S. President's Malaria Initiative (PMI)coreStrategic or Co-development Partner · 1 July 2024Pyramax selected by PMI as optimal malaria treatment supplier. Supports global malaria elimination efforts through procurement programs.
• Tianjin Shin Poong Pharmaceutical Co., Ltd. (천진신풍제약유한공사)majorStrategic or Co-development PartnerJoint venture factory established in Tianjin, China in 1995 - first pharmaceutical joint venture in China by a Korean company. Strategic manufacturing and market access partnership in China.
• Shin Poong Daewoo Pharma Vietnam (신풍대우파마베트남)majorChannel Partner/ Reseller/ DistributorJoint venture factory established in Ho Chi Minh City, Vietnam in 1996. Manufacturing and distribution hub for Southeast Asian markets. Awarded Vietnam Drug Star Award in 2022 and 2024.
• Shin Poong Daewoo Pharma Myanmar (신풍대우파마)minorChannel Partner/ Reseller/ DistributorJoint venture company established in Myanmar in 2001 for local manufacturing and sales of pharmaceutical products.
• Shin Poong Pharma Philippines (신풍파마)minorChannel Partner/ Reseller/ DistributorSales subsidiary established in the Philippines in 2002 for distribution of Shin Poong pharmaceutical products.
• Sudan GMC Factory (아프리카 수단 GMC)minorStrategic or Co-development PartnerJoint venture factory established in Sudan in 2000 for local production and sales of pharmaceuticals in African markets. Expanded in 2002.
• YM Biosciences (Canada)minorStrategic or Co-development PartnerLicensing agreement signed with Canada's YM Biosciences for anti-cancer treatment Tesmilifene in 2005.
• Korea Disease Control and Prevention Agency (KDCA)coreStrategic or Co-development PartnerPyramax officially listed in KDCA Malaria Clinical Practice Guideline 3rd edition (March 2026) as treatment for domestically originated malaria cases in Korea. This follows WHO guidelines for ACT as preferred treatment over chloroquine.
• Korean Society of Gynecologic Oncology (KSGO)minorStrategic or Co-development PartnerAcademic partnership through Shin Hoowel Academic Awards sponsored annually to recognize excellence in gynecologic oncology research. Running since 2021.
• Ansan Vincent Center (안산빈센트병원)minorOthersSocial contribution partnership through 'One Heart Walking Campaign'. Total accumulated donations of 60 million KRW over 4 years (2022-2025) to support low-income and foreign worker healthcare.

Scale indicators8 records

Recent moves13 records

Expansion highlights5 records

Direct peers

• Daehan New Pharm: Korean generic and specialty pharmaceutical manufacturer with strong domestic distribution and OTC portfolio. Comparable scale and product mix including prescription drugs and health functional foods.
• Ildong Pharmaceutical: Korean pharma manufacturer with antibiotics, cardiovascular, and consumer health products. Comparable scale, KOSPI-listed, and overlapping therapeutic categories (antibiotics, cardiovascular).
• Hanmi Pharmaceutical: Korean R&D-driven pharma with proprietary innovative drug pipeline (including FDCs) and global licensing partnerships. Highly comparable on innovation-driven specialty pharma positioning and out-licensing model.
• Daewoong Pharmaceutical: Korean branded and specialty pharmaceutical manufacturer with similar therapeutic breadth including proprietary drugs, biosimilars, and global expansion ambitions. Comparable in scale and listed-status, and competes directly in domestic hospital channels.
• Bukwang Pharmaceutical: Korean specialty pharma focused on CNS, GI, and metabolic disorders with growing international licensing business. Comparable in proprietary specialty drug focus and out-licensing strategy.
• Yuhan Corporation: One of Korea's largest pharmaceutical companies with branded prescription drugs, OTC, and consumer health businesses. Similar product portfolio breadth (prescription drugs, OTC, health functional foods) and KOSPI-listed status make it a direct comparable.
• Chong Kun Dang Pharmaceutical: Korean pharma focused on prescription generics, specialty drugs, and biosimilars. Closely comparable mid-sized domestic manufacturer with similar hospital channel exposure and biosimilar ambitions (e.g., Denosumab).

Broad incumbents

• GC Pharma (Green Cross): Larger established Korean pharmaceutical and blood plasma products company with vaccines, biosimilars, and international operations. Broader portfolio than Shinpoong but overlapping in branded prescription drugs and biosimilars.

Regional players

• Kwang Dong Pharmaceutical: Korean pharma with OTC, health functional foods, and prescription drug portfolios. Overlapping consumer health/AddMiles-style business and similar OTC distribution but historically stronger in consumer channels than prescription.

Others

• Medicines for Malaria Venture (MMV): Not-for-profit product development partnership that co-developed Pyramax with Shinpoong. Not a commercial peer but a strategic partner that shapes the global ACT market and competitor landscape for malaria therapies Shinpoong addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCzH一些
• Xx.com/SPPharm

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SHINPOONG.CO